Les Hopitaux Nord-Ouest

The oncology department at Les Hopitaux Nord-Ouest is actively evaluating immunotherapy approaches for several lung cancer subtypes, aiming to improve survival and disease control.

• KRAS G12C targeted agents combined with checkpoint inhibition
• PD‑L1 blockade maintenance after chemoradiotherapy in limited‑stage small‑cell lung cancer
• Novel bispecific antibodies versus standard chemotherapy
• Combination of MK‑2870 with pembrolizumab for advanced lung disease

The site’s multidisciplinary team collaborates to bring cutting‑edge immune‑based treatments to patients across the region.

A broad portfolio of cancer trials addresses non‑small cell lung cancer, small‑cell lung cancer, large‑cell neuroendocrine carcinoma, and metastatic gastro‑intestinal adenocarcinoma, focusing on new targeted and combination therapies.

• BRAFV600E mutant lung cancer with dual pathway inhibition
• ALK‑positive disease treated with brigatinib‑based regimens
• ROS1‑rearranged NSCLC evaluated with novel tyrosine‑kinase inhibitors
• Addition of Fruquintinib to standard chemotherapy for gastric adenocarcinoma

Les Hopitaux Nord‑Ouest leverages its expertise in thoracic oncology to test innovative strategies that may reshape standard care.

Clinical research at the site includes studies on Alzheimer’s disease‑related psychosis and cognitive decline, seeking therapies that alleviate hallucinations, delusions, and functional impairment.

• New agents targeting neuropsychiatric symptoms in Alzheimer’s
• Combination of KarXT with standard care for mild‑to‑moderate disease
• Assessment of functional outcomes after prophylactic antiseizure medication in intracerebral haemorrhage

The department integrates neurology and psychiatry expertise to address unmet needs in brain health.

Trials targeting chronic lung conditions such as chronic obstructive pulmonary disease and severe allergic asthma evaluate novel anti‑inflammatory agents and strategies to reduce exacerbations.

• Tozorakimab added to standard COPD therapy to lower severe exacerbations
• Omalizumab withdrawal versus continuation in well‑controlled severe asthma
• Bronchiolitis management in pediatric populations
• Long‑term safety monitoring of inhaled therapies in COPD

By focusing on both adult and pediatric respiratory health, the hospital supports comprehensive pulmonary care.

The site participates in vaccine and prophylaxis studies aimed at preventing respiratory syncytial virus infection in infants and reducing disease burden in high‑risk groups.

• Maternal RSV vaccine combined with infant monoclonal antibody prophylaxis
• Evaluation of RSV infection rates following combined immunization strategies
• Monitoring of viral respiratory tract infection outcomes in hospitalized patients

These investigations contribute to national efforts to protect vulnerable newborns from severe viral illness.

Research includes analyses of the economic impact and resource utilization of emerging oncology and respiratory therapies, guiding policy and reimbursement decisions.

• Cost‑effectiveness modeling of immunotherapy versus chemotherapy in lung cancer
• Budget impact assessment of new COPD biologics in the French health system
• Evaluation of hospital workflow efficiency during multi‑drug clinical trials

Les Hopitaux Nord‑Ouest collaborates with health economists to ensure sustainable access to innovative treatments.

Studies address neuropsychiatric manifestations in dementia and other mental health conditions, testing agents that aim to improve cognition and reduce psychotic symptoms.

• ML‑007C‑MA for hallucinations and delusions in Alzheimer’s disease psychosis
• Cognitive enhancement with KarXT in mild‑to‑moderate Alzheimer’s disease
• Assessment of quality of life outcomes in patients receiving psychiatric adjuncts

The interdisciplinary team strives to integrate mental health care within the broader oncology and geriatric services.